WMS-1410

Overview

WMS-1410 is a selective GluN2B -containing NMDA receptor inhibitor with an IC 50 of 18.4 nM. WMS-1410 regulates intracellular calcium levels and protects cells from Apoptosis . WMS-1410 inhibits glutamate-induced excitotoxicity. WMS-1410 reverses NMDA/glycine-induced reduction in glucose-stimulated insulin secretion without altering physiological insulin secretion or baseline redox status, but fails to counteract insulin content loss induced by glucolipotoxicity. WMS-1410 exhibits analgesic activity against advanced neuropathic pain. WMS-1410 can be used in studies related to stroke, brain injury, Alzheimer's disease, Parkinson's disease, type 2 diabetes, and neuropathic pain.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Pain | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Type 2 Diabetes | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > iGluR | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Calcium Channel

Product Information

• Catalog No.: HY-183871
• CAS No.: 1253197-38-4
• Molecular Formula: C20H25NO2
• Molecular Weight: 311.42
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source